Are value stocks finally back for good?
The Covid-19 vaccine might give value investors the lift they’ve been waiting for, says John Stepek. And the UK is a good hunting ground.
That was quick. In last week’s issue, Jim Mellon told Merryn that investors should buy Lloyds Bank (watch the interview at moneyweek.com/videos). Between that issue coming out on Friday, and Wednesday lunchtime, the share price had risen by 20%. Much as we’d like to claim the credit, the main driver was of course the surging hopes for a vaccine (see page 6). Lloyds was just one of many “value” stocks (companies that look cheap on their “fundamentals”, as measured by various financial ratios) to have rallied sharply on the news that we might soon be able to put the misery of intermittent lockdowns behind us.
Value stocks have lagged growth stocks since at least March 2009 (when they had a short-lived blip of outperformance) and we’ve heard many a call that “this must be the turn”. So is this just another false alarm? Or did poor Ted Aronson, who closed his $10bn value-focused hedge fund AJO Partners only last month, actually call the bottom of this cycle when he threw in the towel?
The case for value
Why has growth trounced value so badly? One factor is that in a low interest-rate, low inflation, weak-growth world, fast-growing companies which promise lots of future profits – even if they make very little today – are at a premium. If inflation is low, then investors are happy to wait for their money. Given the choice between a reliable but barely-growing income stream today, or the promise of a pot of gold at the end of a rainbow sometime in the future, investors are happy to wait for the pot of gold. So growth stocks (which could be described as “long duration” assets – see below) do well. But if inflation picks up, it becomes riskier to wait, and cash-generative value looks more appealing.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
So if we’re seeing a turnaround now, it’s because the vaccine news means markets expect economies to open up faster, which means better economic growth, and potentially higher interest rates and inflation to go along with it. Does that seem a reasonable bet? We’d argue that it does. If anything can generate inflation, then huge pent-up demand combined with free-spending governments is surely it. So what should you invest in? The UK is a good option for value. Despite the recent surge in airlines, banks and oil stocks, there’s plenty of room for more. We looked closely at the value-focused Law Debenture (LSE: LWDB) investment trust in last week’s issue and we’re very glad we kept it in our portfolio. If you prefer pure passive, a plain old FTSE 100 tracker will give plenty of exposure to value. And if we’re wrong? Hang on to your holding of Scottish Mortgage (LSE: SMT), just in case – but think about rebalancing.
I wish I knew what duration was, but I’m too embarrassed to ask
“Duration” is a measure of risk that usually relates to bonds. It describes how sensitive a given bond is to movements in interest rates. Think of the relationship between bond prices and interest rates as being like a seesaw: when one side (interest rates) goes up, the other (in this case, bond prices) goes down.
Duration (you can find the measure in the fact sheet of most bond funds) tells you the expected percentage change in a bond’s price in response to a one percentage point (100 basis points) change in interest rates. The higher the duration, the higher the bond’s “interest-rate risk” – that is, the larger the change in price for any given change in rates. This is also known as “modified” duration.
Duration can also refer to the weighted average length of time (in years) it will take to recoup the price paid for a bond in the form of income from its coupons (interest payments) and the return of the original capital. So if a bond has a duration of ten years, that means you have to hold it for ten years to recoup the original purchase price (this is also known as “Macaulay duration”). In practice, both measures of duration return very similar values. So in the above example, the duration value of ten also indicates that a single percentage point rise in interest rates would cause the bond price to fall by 10%.
As a rough guide, the duration of a bond increases along with its maturity – so the longer a bond has to go until it repays its face value, the longer its duration. Also, the lower the yield on the bond, the higher its duration – the longer it takes for you to get paid back. All else being equal, a high-duration bond is riskier (more volatile) than a low-duration bond.
When applied to other assets such as equities (as above), a “long duration” asset refers to the fact that the payback period is lengthy (it takes a while to earn your original investment back) and thus the asset is sensitive to movements in interest rates.
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
John Stepek is a senior reporter at Bloomberg News and a former editor of MoneyWeek magazine. He graduated from Strathclyde University with a degree in psychology in 1996 and has always been fascinated by the gap between the way the market works in theory and the way it works in practice, and by how our deep-rooted instincts work against our best interests as investors.
He started out in journalism by writing articles about the specific business challenges facing family firms. In 2003, he took a job on the finance desk of Teletext, where he spent two years covering the markets and breaking financial news.
His work has been published in Families in Business, Shares magazine, Spear's Magazine, The Sunday Times, and The Spectator among others. He has also appeared as an expert commentator on BBC Radio 4's Today programme, BBC Radio Scotland, Newsnight, Daily Politics and Bloomberg. His first book, on contrarian investing, The Sceptical Investor, was released in March 2019. You can follow John on Twitter at @john_stepek.
-
House prices rise 2.9% – will the recovery continue?
House prices grew by 2.9% on an annual basis in September. Will Budget policies and ‘higher-for-longer’ rates dent the recovery?
By Katie Williams Published
-
Nvidia earnings: what to expect
Nvidia announces earnings after market close on 20 November. What should investors expect from the semiconductor giant?
By Dan McEvoy Published
-
Investing in a dangerous world: key takeaways from the MoneyWeek Summit
If you couldn’t get a ticket to MoneyWeek’s summit, here’s an overview of what you missed
By MoneyWeek Published
-
DCC: a top-notch company going cheap
DCC has a stellar long-term record and promising prospects. It has been unfairly marked down
By Jamie Ward Published
-
Investment trusts could benefit from more optimism
Give yourself an edge with investment trusts. Finding winning stocks is no mean feat.
By Max King Published
-
How investors can use options to navigate a turbulent world
Explainer Options can be a useful solution for investors to protect and grow their wealth in volatile times.
By James Proudlock Published
-
Why the MoneyWeek ETF portfolio won't need to change
Our long-running ETF strategy won’t be placing any bets yet about what Donald Trump will do in his new term
By Cris Sholto Heaton Published
-
Oil sector off the boil: what happens now?
Oil giants BP and Shell are starting to struggle amid a glut of black gold. And growth in demand looks likely to slow
By Dr Matthew Partridge Published
-
Invest in Hilton Foods: a tasty UK food supplier
Hilton Foods is a keenly priced opportunity in an unglamorous sector
By Dr Matthew Partridge Published
-
HSBC stocks jump – is its cost-cutting plan already paying off?
HSBC's reorganisation has left questions unanswered, but otherwise the banking sector is in robust health
By Dr Matthew Partridge Published